Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Celltrion Healthcare Placement: Two Mitigating Factors, Short Healthcare But Long Celltrion

Close Long/Short on Celltrion/Celltrion Healthcare: Market Mood on Placement Is Surprisingly Mild

Celltrion: Understanding Inflectra's U.S. Challenges

Another Negative Sign for Celltrion: Remsima Retail Price Is Falling Too Fast Too Much

Celltrion (068270): Time Is Not Right for Short Sellers Yet

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Celltrion Healthcare   / Equity Capital Markets

<p>Celltrion Healthcare's shareholder, One Equity Partners, is selling USD 355 million of shares via a secondary placement today. This is the first time that One Equity Partners selling down its shares. Besides concerns over increasingly competitive biosimilar market, we believe uncertainties from FDA warning and further sell down will weigh on the stock price. </p>

Celltrion Healthcare's shareholder, One Equity Partners, is selling USD 355 million of shares via a secondary placement today. This is the first time that One Equity Partners selling down its shares. Besides concerns over increasingly competitive biosimilar market, we believe uncertainties from FDA warning and further sell down will weigh on the stock price. 

Celltrion Healthcare Placement: Weigh Down from FDA Uncertainty and Placement Overhang